Vaylen vs Telos Rx: pricing, formats, and approval differences
Vaylen vs Telos Rx pits two cash-pay telehealth options that both offer compounded semaglutide and tirzepatide, but they differ on pricing structure, delivery formats, and how you pay and get refunded. Quick verdict: Vaylen targets prepaid buyers with lower annualized rates and a stated refund if a clinician declines; Telos Rx advertises as-low-as monthly pricing with pay-if-approved policies and less published detail on billing and renewal terms.
Head-to-head summary: what each provider emphasizes
Vaylen emphasizes three formats on one platform: weekly semaglutide injections from $83.25/mo on a 12-month prepaid plan, daily oral semaglutide tablets from $99/mo prepaid, and weekly tirzepatide from $149/mo prepaid. Vaylen requires prepayment for annual plans billed upfront and states a full refund if the clinician declines to prescribe. Telos Rx presents semaglutide as low as $99/mo and tirzepatide as low as $139/mo with pricing described as “if a licensed provider approves you” and notes compounded medications are not FDA-approved.
Distinctive differences at a glance
- Pricing model: Vaylen uses prepaid 12-month plans for headline rates; Telos Rx lists as-low-as monthly rates that depend on approval and plan.
- Formats and molecules: Vaylen offers injectable semaglutide, oral semaglutide tablets, and tirzepatide; Telos Rx offers semaglutide and tirzepatide compounded options.
- Approval and refund language: Vaylen states a full refund if the clinician declines; Telos Rx states pay $0 if not approved on captured landing-page text but provides fewer published billing details.
- Published specifics: Vaylen publishes explicit prepaid monthly equivalents and turnaround claims; Telos Rx provides as-low-as pricing and notes that final price depends on plan and approval.
Comparison table
| Criteria | Vaylen | Telos Rx |
|---|---|---|
| Starting price (semaglutide) | $83.25/mo on 12-month plan or $224/mo monthly | As low as $99 per month |
| Tirzepatide starting price | $149/mo on 12-month plan or $299/mo monthly | As low as $139 per month |
| Formats offered | Weekly injectable semaglutide, daily oral semaglutide tablets, weekly tirzepatide | Compounded semaglutide and tirzepatide |
| Billing model | Prepaid 12-month plans billed upfront for headline rates; month-to-month available at higher price | As-low-as monthly pricing; final price depends on plan and approval |
| Refund if not approved | Full refund for that billing cycle if clinician declines to prescribe | Captured landing page states pay $0 if not approved; fewer published billing details |
| Clinician review timing | Clinician review within 24 hours after form submission | Pricing and eligibility subject to licensed provider approval; timing not published |
| Regulatory note | Compounded medications are not FDA-approved finished products | Compounded medications are not FDA-approved |
Pricing and payment structure compared
Vaylen quotes lower headline monthly equivalents by requiring prepaid 12-month plans billed in one charge. Those headline rates are explicit: semaglutide from $83.25/mo on the 12-month program and oral semaglutide prepaid at $99/mo. Vaylen also publishes month-to-month alternatives at higher rates. Telos Rx lists semaglutide from $99/mo and tirzepatide from $139/mo as “as low as” figures and notes the final price depends on plan and approval. Telos Rx captured text also indicates cancel anytime, no penalties, but captured details about renewal terms and pharmacy arrangements are not published on the captured landing page.
Formats, molecules, and clinical matching
Both providers offer compounded semaglutide and tirzepatide. Vaylen highlights three formats on one platform: injectable semaglutide once weekly, oral semaglutide tablets daily, and weekly tirzepatide, and says a clinician helps choose the right molecule after review. Telos Rx describes semaglutide acting on GLP-1 and tirzepatide acting on GLP-1 plus GIP, with a US-licensed provider deciding which is right for you. The sources do not supply comparative effectiveness data beyond each provider’s messaging on the molecules.
Approval, refunds, and transparency
Vaylen requires you to prepay and then complete a health questionnaire; it states a board-certified US clinician reviews answers within 24 hours and that you receive a full refund for that billing cycle if the clinician declines to prescribe. Telos Rx captured copy repeatedly notes that semaglutide and tirzepatide are prescription-only, compounded, and prescribed only after review by a US-licensed provider and includes language that pay $0 if not approved on the captured landing page, but provides fewer published details about prepaid billing, renewal terms, or unused portions of prepaid plans.
Safety and regulatory note
Both sources explicitly state that compounded medications are not FDA-approved finished products and are not reviewed by the FDA for safety, effectiveness, or quality. Vaylen repeats this regulatory note in multiple disclosures. No additional safety or outcome data beyond each provider’s statements were supplied in the captured evidence.
Conclusion: Choose based on payment style and format needs
Vaylen vs Telos Rx centers on whether you prefer lower prepaid headline rates and multiple delivery formats or as-low-as monthly pricing with less-published prepaid detail. Choose Vaylen if you want lower annualized rates, a platform that offers injectable and oral semaglutide plus tirzepatide, and an explicit refund if a clinician declines. Choose Telos Rx if you prefer as-low-as monthly pricing presented up front and want to confirm plan, renewal, and state coverage details directly with the provider. The primary keyword Vaylen vs Telos Rx summarizes the tradeoffs above.